Power Law company profile

Momenta Pharmaceuticals

Biotech & Life Sciences · Cambridge, United States · Founded 2001 · IPO 2004 Unicorn

Biotechnology company specializing in the characterization and process engineering of complex molecules

Valuation

$6.50B

Market cap · 2026

Revenue

$29M

Latest reported FY

Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026 $10B+ revenueThoroughbred · Power Law outcome

Investors

5 investors on Momenta Pharmaceuticals's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 1 investor entered at this stage

Polaris Partners

Series B+ 4 investors entered at this stage

MVM Life Science Partners

Mithra Ventures

Atlas Venture

Cardinal Partners

Momenta Pharmaceuticals mafia

Startups founded by Momenta Pharmaceuticals alumni

Former Momenta Pharmaceuticals employees who went on to start their own companies. Sorted by Dealroom signal score.

Ottimo PharmaEst. 2017

Kathryn GoldenUnited Kingdom

Signal score80

Mitra BiotechEst. 2009

MSMallik SundaramUnited States

Signal score79

OvaScienceEst. 2011

Christoph WestphalUnited States

Signal score61

VisterraEst. 2007

Ram SasisekharanUnited States

Signal score60

Book a demo to explore the full alumni network →

Global footprint

Where Momenta Pharmaceuticals has talent and traffic

Workforce by country

2 countries with
team presence

🇺🇸 United States96%

🇮🇳 India4%

2 countries shown

Web traffic by country

1.8K monthly visits
across markets

🇺🇸 United States66.7%

🇵🇭 Philippines16.7%

🇬🇧 United Kingdom11.1%

🇹🇭 Thailand5.6%

Top 4 markets shown

Patent intelligence

$78M patent portfolio · 63 active families

Estimated portfolio value

$78M

1.2% of market cap · 26× smaller than top peer Ablynx ($2B)

63 active patent families

Where Momenta Pharmaceuticals innovates Molecular biologyPolysaccharideGlycanCell biologyChemistry

Where Momenta Pharmaceuticals concentrates vs peers

Each axis is a top-10 topic across Momenta Pharmaceuticals and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Momenta Pharmaceuticals

An AI-synthesized read of the highest-engagement posts about Momenta Pharmaceuticals on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Momenta Pharmaceuticals on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles